Table 1.
Markers | Mouse | Human |
---|---|---|
Monocyte | CD11b, Ly6C, CD192 (CCR2), CX3CR1 | CD11b, CD14, CD16 |
Macrophage | CD11b, F4/80, CD68, CD64 | CD11b, CD68, CD163 |
Proinflammatory | CD86, MHCII | CD86, HLA-DR |
Anti-inflammatory | CD206 (MRC1), IL-4R | CD206 (MRC1), IL-4R |
Tissue resident | CD192 (CCR2), CD206 (MRC1), CD68, CD74, CD81 | CD192 (CCR2), CD68, CD74, CD81 |
Dendritic cell | CD11c, CD11b, MHCII | CD11c, CD11b, HLA-DR |
Conventional | CX3CR1, CD103 | CD1c (BDCA1), HLA-DR |
Plasmacytoid | Ly-49Q, CD317 (Bst2) | CD123 (IL-3Rα), CD303 (BDCA2) |
Neutrophil | CD11b, Ly6G, CD18 | CD11b, CD16, CD32, CD66b |
Eosinophil | CD170 (Siglec-F), CD193 (CCR3) | CD329 (Siglec-8), CD193 (CCR3) |
Basophil | CD123 (IL-3Rα), FcεRIα | CD123 (IL-3Rα), FcεRIα |
Mast cell | CD117 (c-Kit), FcεRIα | CD32, CD117 (c-Kit), FcεRIα |
Detection of myeloid (CD45+) cell types by flow cytometry. Combinations and level of marker expression can vary with subtype/state of activation. Ly6C, lymphocyte antigen 6; CCR2, C-C chemokine receptor type 2; CX3CR1, CX3 chemokine receptor 1; MHCII, major histocompatibility complex II; HLA-DR, human leukocyte antigen–DR isotype; MRC1, mannose receptor C-type 1; IL4R, interleukin-4 receptor; BDCA1, blood dendritic cell antigen 1; Bst2, bone marrow stromal cell antigen 2; IL-3Rα, interleukin-3 alpha receptor; BDCA2, blood dendritic cell antigen 2; Ly6G, lymphocyte antigen 6 complex locus G6D; CCR3, C-C chemokine receptor type 3; FcεRIα, Fc epsilon alpha receptor I.